Bayesian Health vs Implicity

Implicity raised a EUR 35M growth round on September 9, 2026, led by IRIS with Five Arrows. Its buyer is a cardiology device clinic following pacemakers, ICDs and loop recorders from Abbott, Biotronik, Boston Scientific, Medtronic and MicroPort, which the vendor calls manufacturer-agnostic. FDA lists three 510(k) clearances for Implicity, IM007 (K210543), SignalHF for heart failure risk (K230842) and the ILR ECG Analyzer (K253463). The two papers with Implicity authors cover its insertable-monitor algorithm and its AF alert filtering. PubMed lists no peer-reviewed validation under SignalHF, and the vendor cites Health Data Hub data and a 26% mortality reduction against conventional remote monitoring.

Bayesian Health is a Johns Hopkins spinout whose FDA-cleared sepsis flag descends from the TREWS system, and the inpatient sepsis lead at a Medicare hospital is the person who buys it. SignalHF scores heart failure risk from implanted-device data in outpatient follow-up, while Bayesian reads inpatient EHR data for sepsis, so each answers to a different clinical owner.